Cart
sales@molnova.com
BMS-P5 free base
CAS No. 1550371-22-6
BMS-P5 free base( —— )
Catalog No. M22888 CAS No. 1550371-22-6
BMS-P5 free base is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor.?BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 74 | In Stock |
|
| 10MG | 131 | In Stock |
|
| 25MG | 267 | In Stock |
|
| 50MG | 480 | In Stock |
|
| 100MG | 683 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBMS-P5 free base
-
NoteResearch use only, not for human use.
-
Brief DescriptionBMS-P5 free base is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor.?BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma.
-
DescriptionBMS-P5 free base is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor.?BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma.?Administration of BMS-P5 to multiple myeloma-bearing mice delays appearance of symptoms and disease progression Targeting PAD4 may be beneficial for treatment of multiple myeloma.Administration of BMS-P5 to multiple myeloma-bearing mice delays appearance of symptoms and disease progression.?
-
In VitroCell Viability Assay.Cell Line:Neutrophils.Concentration:10 μM and 100 μM.Incubation Time:30 min followed by addition of DP42 or 5TGM1 CM.Result:Prevented MM-induced NET formation.
-
In VivoAnimal Model:Syngeneic mouse model of MM.Dosage:50 mg/kg.Administration:Oral gavage, twice a day beginning on day 3 after tumor cell injection.Result:Significantly delayed development of symptoms and significantly prolonged survival of MM-bearing mice.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptorpeptidylarginine deiminase 4 (PAD4)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1550371-22-6
-
Formula Weight472.58
-
Molecular FormulaC27H32N6O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (529.01 mM)
-
SMILESO=C(N1[C@@H](C)CC[C@@H](N)C1)C2=CC(OC)=C3C(N=C(C4=CC5=CC=CN=C5N4CC6CC6)N3C)=C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Li M , Lin C , Deng H , et al. A novel peptidylarginine deiminase 4 (PAD4) inhibitor BMS-P5 blocks formation of neutrophil extracellular traps and delays progression of multiple myeloma[J]. Molecular Cancer Therapeutics, 2020, 19(7):molcanther.1020.2019.
molnova catalog
related products
-
Emicizumab
Emicizumab(ACE 910) is a bispecific monoclonal antibody that bridges activated factor IX and activated factor X to mimic the function of activated factor VIII. Emicizumab is used for the prevention and treatment of hemophilia A.
-
Cenobamate
Cenobamate (YKP-3089, YKP3089) is a potential anti-seizure agent with currently unknown mechanisms of action.
-
Combretol
Combretol has leishmanicidal activity, it showed moderate activity (growth inhibition 87.3 and 73.0 %, respectively, at 50 μM) against a multidrug-resistant L. tropica line. Combretol also shows weakly active cytotoxic activity.
